Literature DB >> 26876581

JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2.

Yasuhiro Asahina1, Namiki Izumi2, Kumada Hiromitsu3, Masayuki Kurosaki2, Kazuhiko Koike4, Fumitaka Suzuki3, Hajime Takikawa5, Atsushi Tanaka5, Eiji Tanaka6, Yasuhito Tanaka7, Hirohito Tsubouchi8, Norio Hayashi9, Naoki Hiramatsu10, Hiroshi Yotsuyanagi11.   

Abstract

Entities:  

Year:  2016        PMID： 26876581     DOI： 10.1111/hepr.12645

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  18 in total

Review 1.  Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature.

Authors:  Yasuo Tanaka; Ryosuke Tateishi; Kazuhiko Koike
Journal:  Clin J Gastroenterol       Date:  2019-05-27

2.  Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.

Authors:  Tomomi Okubo; Masanori Atsukawa; Akihito Tsubota; Hidenori Toyoda; Noritomo Shimada; Hiroshi Abe; Keizo Kato; Korenobu Hayama; Taeang Arai; Ai Nakagawa-Iwashita; Norio Itokawa; Chisa Kondo; Chiaki Kawamoto; Etsuko Iio; Yasuhito Tanaka; Takashi Kumada; Katsuhiko Iwakiri
Journal:  Hepatol Int       Date:  2018-03-29       Impact factor: 6.047

3.  Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan.

Authors:  Hideki Hagiwara; Yoshiki Ito; Takashi Ohta; Yasutoshi Nozaki; Takayuki Iwamoto; Atsushi Hosui; Naoki Hiramatsu; Yuki Tahata; Ryotaro Sakamori; Hayato Hikita; Norio Hayashi
Journal:  JGH Open       Date:  2022-05-18

Review 4.  Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.

Authors:  Goki Suda; Koji Ogawa; Megumi Kimura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
Journal:  J Clin Transl Hepatol       Date:  2016-12-26

5.  Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.

Authors:  Preethi Krishnan; Gretja Schnell; Rakesh Tripathi; Jill Beyer; Thomas Reisch; Tatyana Dekhtyar; Michelle Irvin; Wangang Xie; Bo Fu; Margaret Burroughs; Rebecca Redman; Hiromitsu Kumada; Kazuaki Chayama; Christine Collins; Tami Pilot-Matias
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Kyohei Kishino; Yoshihiro Shimono; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Akio Ishii; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.

Authors:  Takeshi Hirayama; Tadashi Ikegami; Akira Honda; Teruo Miyazaki; Sho-Ichiro Yara; Motoyuki Kohjima; Makoto Nakamuta; Yasushi Matsuzaki
Journal:  Intern Med       Date:  2017-12-27       Impact factor: 1.271

8.  Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.

Authors:  Kazuaki Chayama; Fumitaka Suzuki; Yoshiyasu Karino; Yoshiiku Kawakami; Ken Sato; Tomofumi Atarashi; Atsushi Naganuma; Tsunamasa Watanabe; Yuichiro Eguchi; Hitoshi Yoshiji; Masataka Seike; Yoshiyuki Takei; Koji Kato; Katia Alves; Margaret Burroughs; Rebecca Redman; David L Pugatch; Tami J Pilot-Matias; Preethi Krishnan; Rajneet K Oberoi; Wangang Xie; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2017-09-25       Impact factor: 7.527

9.  The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.

Authors:  Hiromitsu Kumada; Yoshiyuki Suzuki; Yoshiyasu Karino; Kazuaki Chayama; Norifumi Kawada; Takeshi Okanoue; Yoshito Itoh; Satoshi Mochida; Hidenori Toyoda; Hitoshi Yoshiji; Shintaro Takaki; Naoyoshi Yatsuzuka; Etsuo Yodoya; Takashi Iwasa; Go Fujimoto; Michael N Robertson; Stuart Black; Luzelena Caro; Janice Wahl
Journal:  J Gastroenterol       Date:  2016-11-21       Impact factor: 6.772

10.  Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases.

Authors:  Ayumi Sugiura; Satoru Joshita; Yuki Yamashita; Tomoo Yamazaki; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Shuichi Wada; Hiromitsu Mori; Soichiro Shibata; Kaname Yoshizawa; Susumu Morita; Kiyoshi Furuta; Atsushi Kamijo; Akihiro Iijima; Satoko Kako; Atsushi Maruyama; Masakazu Kobayashi; Michiharu Komatsu; Makiko Matsumura; Chiharu Miyabayashi; Tetsuya Ichijo; Aki Takeuchi; Yuriko Koike; Yukio Gibo; Toshihisa Tsukadaira; Hiroyuki Inada; Yoshiyuki Nakano; Seiichi Usuda; Kendo Kiyosawa; Eiji Tanaka; Takeji Umemura
Journal:  Biomedicines       Date:  2020-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.